Alvine Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alvinepharma.com
Clinical Trials
13
Active:6
Completed:6
Trial Phases
2 Phases
Phase 1:5
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (62.5%)Phase 2
3 (37.5%)Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Alvine Pharmaceuticals Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT01917630
Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients
Completed
- Conditions
- Celiac Disease
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Alvine Pharmaceuticals Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT01560169
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Kaiser Permanente Southern California, Allergy Department, San Diego, California, United States
🇺🇸University of Colorado, Denver, Aurora, Colorado, United States
Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
Phase 2
Completed
- Conditions
- Celiac Disease
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Alvine Pharmaceuticals Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01255696
- Locations
- 🇫🇮
Terveystalo Kuopio, Kuopio, Finland
🇫🇮Oulu Diakonissalaitos (ODL), Oulu, Finland
🇫🇮FINN-MEDI Research Oy - Clinical Trials Center, Tampere, Finland
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
Phase 2
Completed
- Conditions
- Celiac Disease
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Alvine Pharmaceuticals Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00959114
- Locations
- 🇫🇮
FINN-MEDI Research - Clinical Trials Center, Tampere, Finland
Effects of Gluten Digestion With ALV003
Completed
- Conditions
- Celiac Disease
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- Alvine Pharmaceuticals Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00859391
- Locations
- 🇦🇺
Nucleus Networks Limited, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- Next
News
No news found